Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Nu Holdings
NU
5
Liberty Latin America-A
LILA
US OptionsDetailed Quotes
AKRO250516P55000
- 13.10
- 0.000.00%
15min DelayClose Apr 24 15:59 ET
0.00High0.00Low
13.10Open13.10Pre Close0 Volume5 Open Interest55.00Strike Price0.00Turnover102.76%IV-2.22%PremiumMay 16, 2025Expiry Date14.01Intrinsic Value100Multiplier21DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.8549Delta0.0230Gamma2.81Leverage Ratio-0.0497Theta-0.0216Rho-2.40Eff Leverage0.0226Vega
Akero Therapeutics Newsroom
Evercore Maintains Akero Therapeutics(AKRO.US) With Buy Rating, Raises Target Price to $60
Analysts Offer Insights on Healthcare Companies: Akero Therapeutics (AKRO), Immunovant (IMVT) and 4D Molecular Therapeutics (FDMT)
Akero Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Akero Therapeutics Analyst Ratings
Bank of America Securities Remains a Buy on Akero Therapeutics (AKRO)
LifeSci Capital Maintains Akero Therapeutics(AKRO.US) With Buy Rating, Maintains Target Price $80
Akero Therapeutics: Strong Financial Health and Promising Clinical Trial Results Drive Buy Rating
Phillip Securities Reaffirms Their Buy Rating on Akero Therapeutics (AKRO)
UBS Adjusts Price Target on Akero Therapeutics to $109 From $42, Keeps Buy Rating
UBS Maintains Akero Therapeutics(AKRO.US) With Buy Rating, Raises Target Price to $109
Akero Therapeutics Raised to Buy From Neutral by B of A Securities
Akero Therapeutics Analyst Ratings
BofA Securities Upgrades Akero Therapeutics(AKRO.US) to Buy Rating, Raises Target Price to $63
J.P. Morgan Keeps Their Buy Rating on Akero Therapeutics (AKRO)
Morgan Stanley Maintains Overweight on Akero Therapeutics, Raises Price Target to $96
Morgan Stanley Maintains Akero Therapeutics(AKRO.US) With Buy Rating, Maintains Target Price $96
A Quick Look at Today's Ratings for Akero Therapeutics(AKRO.US), With a Forecast Between $50 to $96
Citigroup Maintains Buy on Akero Therapeutics, Raises Price Target to $80
Canaccord Genuity Maintains Buy on Akero Therapeutics, Raises Price Target to $73
Akero Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Market Insights
Warren Buffett Portfolio Warren Buffett Portfolio
Buffett's holdings are the latest portfolio from Berkshire Hathaway. Regarded as a top investor, his trades often signal the market and influence the industry. Buffett's holdings are the latest portfolio from Berkshire Hathaway. Regarded as a top investor, his trades often signal the market and influence the industry.
Unlock Now
Discussing
2025 Buffett shareholders' meeting: What's the new buzz in value investing?
🎙️Discussion 1. In the face of market changes, do you prefer to stick with growth stocks or switch to value stocks? 2. Based on the current
Moomoo News Global
Apr 9 20:29
Learning From Buffett: Investing Wisely Amid Market Volatility Triggered by Trump's Tariffs
Discussing
FOMC holds rates amid heightened uncertainty: Where will US stocks head next?
🎙️Discussion 1. With the Fed highlighting "elevated uncertainty", are you prioritizing rate projections or near-term economic data for ma
Moo Live
Mar 20 02:25
FOMC Press Conference, March 19, 2025
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Unlock Now
